SDGR vs RXRX
SDGR and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | — | $1.88B |
| P/S | — | 25.4x |
| Revenue | $259.04M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 26.9% |
| Net income | -$54.34M(TTM) | — |
| Earnings growth (YoY) | 44.8% | -39.1% |
| EPS, diluted | $-0.73(TTM) | — |
| EBIT margin | -65.2% | -867.9% |
| ROE | -31.4% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | +53.8% | -27.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: SDGR frente a RXRX
| Métrica | SDGR | RXRX |
|---|---|---|
| Valor final | $3.9K | $1.1K |
| Retorno total | -61.2% | -88.7% |
| CAGR | -16.0% | -33.1% |
| Volatilidad | 63.8% | 92.6% |
| Sharpe | -0.03 | -0.04 |
| Sortino | -0.04 | -0.06 |
| Caída máxima | -86.0% | -93.1% |
Basado en 1362 días de negociación comunes, 2021-04-16 → 2026-09-17 · tasa libre de riesgo 4.12% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)